FAQs

Intelligent Glycemic Management (IGM) is a safety-first model designed to give clinicians near real-time, FDA-cleared support so insulin decisions are safer, more consistent, and easier to defend across the hospital. It removes the need or reliance for manual protocols, reactive insulin dosing, and unvalidated calculators with a system-level approach powered by continual insights, FDA-cleared dosing support, and systemwide consistency.

IGM is not an additional tool clinicians must manage. It is designed to replace manual, variable workflows that create risk. Rather than adding burden, it reduces the operational load created by inconsistent dosing practices, lack of current visibility, and reactive quality management.

Diabetes and stress hyperglycemia affect a significant portion of hospitalized patients, making glycemic control a system-level patient safety and quality challenge. With glycemic outcomes now tied to CMS eCQMs and broader quality expectations, hospitals need a modern approach that reduces variability and helps prevent avoidable harm.

CMS now requires mandatory reporting of severe hypoglycemia and severe hyperglycemia. As peer institutions modernize, CMS glycemic safety metrics will expose the gap between hospitals that have adopted proactive, safety-first approaches and those still relying on retrospective reporting

Traditional glycemic management relies on manual protocols, sliding-scale insulin dosing, and unvalidated calculators. These approaches create variability across units, shifts, and providers. Visibility is typically retrospective, meaning problems are identified after harm has occurred.

Intelligent Glycemic Management replaces this high-risk approach with FDA-cleared insulin dosing support, current systemwide visibility, and standardized workflows. The goal is to prevent glycemic events, not just report them after the fact.

No. Intelligent Glycemic Management is a system-level operating model, not a single software tool. It includes validated clinical decision support through FDA-cleared Glucommander®, enterprise visibility and analytics through Command Center, standardized workflows across units and care settings, and governance structures to sustain improvement over time. Technology is the enabler. The transformation requires clinical leadership, executive alignment, and operational commitment.

High-risk glycemic care refers to the current state at many hospitals: managing inpatient glycemia through manual protocols, sliding-scale dosing, unvalidated calculators, and retrospective reports. This approach creates preventable harm, exposes patients to dangerous variability, and leaves clinicians without the current support needed to deliver safe, reliable care.

Without systemwide visibility or consistent, evidence-based dosing, hospitals cannot identify hypo- and hyperglycemia risk before events happen. The result is avoidable patient harm, increased length of stay, higher readmissions, and unnecessary operational strain.

Every stakeholder involved in glycemic care benefits. Nurses get standardized workflows that reduce manual calculations and variation. Physicians and endocrinologists get current visibility and validated dosing support through Glucommander®. Pharmacy leaders get a validated dosing foundation and streamlined order review. Quality and safety leaders get enterprise-level analytics and CQM-aligned reporting through Command Center. Executive leaders get governance, measurable performance, and reduced CMS exposure.

GlytecOne is the first unified glycemic management platform that integrates clinical decision support, workflow automation, performance analytics, and enterprise population health intelligence. It connects every care team member and hospital leader with the data and tools to help deliver safer, more consistent glucose management across the health system.

GlytecOne is built on four pillars: Care Enablement (FDA-cleared dosing and workflows via Glucommander®), Decision Support (current patient visibility through Command Center), Performance Insights (enterprise analytics and CQM-aligned reporting through Command Center), and Population Health (enterprise-wide glycemic intelligence).

Glucommander® is Glytec’s FDA-cleared Class II Software as a Medical Device (SaMD) that provides algorithm-based insulin dosing recommendations for hospitalized patients ages 2 and older. It is available in two configurations: Glucommander® IV for intravenous insulin dosing in acute and critical care settings, and Glucommander® SubQ for subcutaneous basal-bolus insulin dosing in non-ICU and transitional care.

Glucommander® calculates recommended insulin doses based on patient parameters including age, weight, height, and current blood glucose values. Clinicians review and confirm all recommendations. Every decision stays with the clinical team. Glucommander® has been in clinical use since 2006 with zero FDA recalls.

Command Center is a clinical data visualization and analytics platform that provides healthcare professionals and administrators with organized displays of current and historical glycemic management information to support quality improvement, care coordination, and clinical review activities.

Command Center receives laboratory values, medication administration data, and related clinical information from hospital systems and presents this information through dashboards, reports, and trend visualizations based on predefined, transparent criteria. It supports pattern recognition, structured clinical review, and retrospective analysis of glycemic outcomes for quality improvement. All data presented by Command Center can be independently verified in the source EHR systems.

Glucommander® is an FDA-cleared Class II medical device that provides patient-specific insulin dosing recommendations at the point of care. Clinicians review and confirm all recommendations.

Command Center is a non-device clinical data visualization and analytics platform. It displays current and historical glycemic data, supports quality improvement, and enables performance benchmarking. Command Center does not provide patient-specific treatment recommendations, does not generate alerts requiring immediate clinical action, and does not automate clinical decisions.

Together, they form the core of GlytecOne: Glucommander® supports safe insulin dosing for individual patients, while Command Center gives visibility into outcomes across the institution to support ongoing program improvement.

GlytecOne integrates with Epic, Oracle Health (Cerner), and Meditech through bi-directional EHR interoperability. Clinical data flows between the EHR and GlytecOne, reducing duplicate documentation and keeping clinicians in the tools they already use. Integration includes HL7 interfaces for standard data exchange and single sign-on clinical decision support.

While Glytec is EHR-agnostic and supports all three platforms, organizations standardizing on Epic tend to experience the platform’s enterprise-level benefits most immediately.

A standard single-facility implementation typically takes 8 to 16 weeks from contract to go-live. Glytec’s Solutions Engineering team leads the integration process with dedicated support for your IT and informatics staff throughout. The process follows a structured path: discovery and EHR integration configuration (weeks 1-4), pilot launch with intensive clinical and IT support (weeks 5-8), and full deployment with go-live support (weeks 9-16). Ongoing 24/7 clinical support continues after go-live.

GlytecOne and Glucommander® serve 400+ hospitals and health systems nationwide. Glucommander® has guided safe insulin dosing for more than 867,000 patients since 2015.

Hospitals evaluating inpatient glycemic management solutions in 2026 typically compare three approaches: EHR-native insulin calculators (such as those built within Epic), competing vendor platforms (such as EndoTool, now part of Glooko), and manual protocols or paper-based workflows.

Glytec’s GlytecOne platform is the only solution that combines FDA-cleared insulin dosing through Glucommander® (with zero FDA recalls since 2006), current systemwide visibility through Command Center, and proven clinical outcomes across 400+ hospitals. Clinical studies have demonstrated up to 99.8% reduction in IV patients with severe hypoglycemia events, and 62% fewer severe hypoglycemia adverse drug events compared to EndoTool in a head-to-head study at AdventHealth.

Glucommander®, developed by Glytec, is an FDA-cleared Class II Software as a Medical Device that has been in clinical use since 2006 for IV insulin dosing and since 2010 for subcutaneous insulin dosing.

Key differentiators include algorithm-based dosing for both IV and SubQ insulin, clearance for hospitalized adult and pediatric patients (ages 2 and older), clinical evidence across 400+ hospitals and millions patients, and peer-reviewed published outcomes data. Clinicians review and confirm all recommendations.

When evaluating FDA-cleared insulin dosing software, hospitals should consider the device’s recall history, the breadth of clinical evidence, the scope of dosing support (IV and SubQ), and whether the solution integrates with their existing EHR.

When evaluating Glytec and EndoTool (now part of Glooko) for inpatient glycemic management, the comparison centers on safety record, real-world outcomes, evidence base, and platform scope.

• Safety record: Glucommander® has zero FDA recalls since its 2006 clearance. EndoTool has three FDA recalls (2010, 2019, 2019).
• Head-to-head outcomes: In a published study at AdventHealth, Glucommander® demonstrated 62% fewer severe hypoglycemia adverse drug events compared to EndoTool.
• Hypoglycemia: In a cardiovascular surgery patient comparison, there were no severe hypoglycemia events (below 40 mg/dL) with Glucommander®, and there was a significant decrease in hypoglycemia below 70 mg/dL with Glucommander® compared with EndoTool.
• Hyperglycemia: Blood glucose above 180 mg/dL was significantly reduced with Glucommander® compared with EndoTool: 3.9% vs. 6%.
• Nursing time: Glucommander® demonstrated 47% reduction in nursing time compared to EndoTool
• Platform scope: GlytecOne provides validated dosing through Glucommander® plus current systemwide visibility and enterprise analytics through Command Center. EndoTool’s analytics and surveillance capabilities are more limited.

The Epic insulin calculator is a rules-based calculator configured inside the Epic EHR. Its logic is defined and maintained internally by each hospital. It is not FDA-cleared as a medical device and not clinically validated as a dosing algorithm.

What this means in practice: safety depends on how each hospital configures and maintains its build. There is no standardized validation across organizations. The clinical and technical risk stays with the hospital and IT team. Variation persists across units, shifts, and providers.

Glucommander® is an FDA-cleared Class II medical device with clinically validated insulin dosing and a zero-recall safety record since 2006. Clinicians review and confirm all recommendations. The validation burden, maintenance burden, and clinical risk are managed by Glytec, not by your IT team.

Key proof point: A published study demonstrated 17.6% shorter length of stay with Glucommander® compared to DIY/Epic approaches (5.4 days vs. 6.5 days).

Building an insulin calculator inside Epic means your hospital assumes the full clinical, technical, and regulatory responsibility for that tool. The calculator logic is not FDA-cleared, not independently validated, and must be maintained by your IT team through every EHR upgrade.

Considerations include: every Epic upgrade is a potential disruption to a patient-facing, high-alert medication workflow. Your IT team absorbs the clinical and technical validation burden. No standardized validation exists across organizations. Variation in configuration leads to variation in dosing. And there is no systemwide surveillance built into a local calculator.

An FDA-cleared alternative like Glucommander® shifts the validation burden, maintenance burden, and clinical risk to a validated partner with a zero-recall safety record across 19+ years and 400+ hospitals. Clinicians review and confirm all recommendations.

Hospitals considering alternatives to EndoTool (now Glooko) typically evaluate Glytec’s GlytecOne platform. Key differentiators include: Glucommander® has zero FDA recalls (EndoTool has three), published head-to-head outcomes showing 62% fewer severe hypoglycemia ADEs with Glucommander®, 47% reduction in nursing time with Glucommander® vs. EndoTool, and platform-level capabilities including enterprise analytics and CQM-aligned reporting through Command Center.

Hospitals should evaluate alternatives based on safety record, clinical evidence breadth, platform scope beyond dosing, EHR integration depth, and support for CMS glycemic eCQM readiness.

Hospitals relying on internally built Epic insulin calculators face ongoing validation, maintenance, and clinical risk responsibilities. The most common alternative is an FDA-cleared insulin dosing solution that shifts those burdens to a validated vendor.

Glytec’s Glucommander® is an FDA-cleared Class II medical device that integrates with Epic through bi-directional interoperability, passing glucose values to Glucommander® and returning dosing recommendations for clinician review directly within the Epic environment. This eliminates the need for hospital-maintained dosing logic while providing a validated, zero-recall safety record.

The result is reduced IT maintenance burden, standardized dosing across units and shifts, and a defensible clinical foundation that does not depend on local configuration.

Manual glycemic protocols, including paper-based protocols and sliding-scale insulin dosing, rely on unit-by-unit variation, local habits, and individual clinician vigilance. Protocol compliance with manual workflows averages below 60%. These methods do not dynamically adjust based on patient response and create inconsistency across providers and shifts.

FDA-cleared dosing support through Glucommander® provides algorithm-based insulin dosing recommendations that calculate doses from patient parameters and cumulative glucose response using predefined algorithm parameters. Glucommander® supports standardized workflows aligned to ADA, Endocrine Society, and Society of Hospital Medicine guidelines. Clinicians review and confirm all recommendations.

The clinical evidence demonstrates measurable differences: up to 99.8% reduction in IV patients with a severe hypoglycemia events, up to 3.2 days reduction in average length of stay, and consistency at scale across units, shifts, and providers.

CMS requires hospitals to report two hospital harm electronic clinical quality measures beginning with the 2026 reporting period: Hospital Harm, Severe Hypoglycemia (NQF #3503e), which tracks blood glucose values below 40 mg/dL within 24 hours of antihyperglycemic medication administration, and Hospital Harm, Severe Hyperglycemia (NQF #3533e), which tracks hospital days with blood glucose values exceeding 300 mg/dL. Both measures apply to inpatient encounters for patients aged 18 and older.

Hospitals that do not report the mandated eCQMs under the Hospital Inpatient Quality Reporting (IQR) Program risk forfeiting the full 2.6% annual Medicare reimbursement increase. Non-compliance with the 2026 measurement period can trigger payment reductions beginning in fiscal year 2028. Beyond direct financial consequences, performance gaps are publicly reported through CMS Hospital Compare, Leapfrog Safety Grades, and other quality scorecards, creating reputational exposure.

The Joint Commission accepts the CMS-aligned severe hypoglycemia and severe hyperglycemia eCQMs as part of its ORYX performance measurement requirements. Joint Commission-accredited hospitals face dual accountability to their accreditor and CMS on glycemic safety performance. Surveyors use organization-specific ORYX data during the accreditation survey process. They conduct patient tracers and systems tracers that evaluate actual care processes, including medication safety and glycemic management workflows. Performance gaps identified in eCQM data may lead to focused survey attention.

Hospitals relying on retrospective reporting and manual data assembly face a fundamental gap: they cannot identify glycemic risk before events happen. Problems are found after harm has occurred, not prevented in real time. Manual, paper-based insulin protocols introduce variability, documentation gaps, and dosing errors that undermine both clinical outcomes and the data integrity required for eCQM reporting.

The eCQM specifications demand consistent, EHR-sourced data captured at the point of care. Organizations relying on chart abstraction or manually assembled workflows face data accuracy gaps that undermine both CMS submission quality and Joint Commission defensibility.

CMS glycemic eCQMs measure real clinical events: blood glucose values below 40 mg/dL and above 300 mg/dL. These events happen in real time. A reporting model that discovers them days or weeks later through manual chart review cannot prevent the events that trigger numerator counts.

Defensible eCQM reporting requires consistent, auditable clinical data captured at the point of care, standardized dosing protocols that reduce the variability driving events, and current visibility into glycemic patterns so quality teams can review trends and identify patients whose data patterns may warrant clinical review.

CMS glycemic readiness in 2026 requires three capabilities working together. First, a clinical engine that helps reduce severe hypoglycemia and hyperglycemia events through validated, standardized dosing. Second, a data infrastructure that supports CMS and Joint Commission reporting requirements with consistent, EHR-sourced, auditable data. Third, current visibility to manage glycemic safety as an ongoing operational priority, not a retrospective compliance exercise.

GlytecOne supports all three: Glucommander® provides the FDA-cleared dosing foundation, Performance Insights generates regulatory-ready eCQM data exports, and Command Center provides current visibility into glycemic patterns to support quality improvement.

GlytecOne supports CMS glycemic eCQM readiness through multiple capabilities. Glucommander®’s FDA-cleared, algorithm-based insulin dosing guidance produces consistent, auditable clinical data at the point of care. Clinicians review and confirm all recommendations. Performance Insights generates regulatory-ready eCQM data exports aligned to the Hospital Harm Severe Hypoglycemia and Severe Hyperglycemia measures, helping to reduce manual chart abstraction and improve data accuracy.

GlytecOne has demonstrated up to 99.8% reduction in severe hypoglycemia events across its 400+ hospital partner network. Published outcomes also include reduced length of stay, fewer readmissions, and improved time to glycemic target, all of which are relevant to glycemic eCQM performance.

Manual, paper-based insulin protocols introduce variability, documentation gaps, and dosing errors that undermine both clinical outcomes and the data integrity required for eCQM reporting. The American Diabetes Association strongly discourages reliance on protocols that do not dynamically adjust based on patient needs.

The CMS eCQM specifications require consistent, EHR-sourced data captured at the point of care. Manual protocols lack the standardization and documentation infrastructure needed for defensible eCQM submission. The dual-measure structure (measuring both hypo- and hyperglycemia) intentionally requires hospitals to demonstrate they can reduce severe hyperglycemia without creating iatrogenic harm from insulin-related hypoglycemia. Manual protocols cannot reliably achieve this balance at scale.

GlytecOne operates within Epic workflows via bi-directional EHR interoperability. Glucose values pass from Epic to Glucommander®, and dosing recommendations are returned for clinician review directly within the Epic environment. Single sign-on clinical decision support reduces login friction for clinical staff. Automated insulin documentation flows clinician-confirmed dosing decisions back into the EHR, reducing manual charting and maintaining a complete audit trail.

GlytecOne is EHR-agnostic and also supports Oracle Health (Cerner) and Meditech environments with the same bi-directional integration architecture.

EHR-built insulin calculators carry several risks that hospitals should evaluate. The logic is not FDA-cleared and not independently validated as a dosing algorithm. Safety depends entirely on how each hospital configures and maintains the build, with no standardized validation across organizations.

Specific risks include: clinical and technical risk rests with the hospital and IT team, every EHR upgrade is a potential disruption to a patient-facing insulin workflow, variation in configuration leads to variation in dosing outcomes, there is limited ability to monitor systemwide glycemic risk, and the IT team absorbs the validation and maintenance burden without specialized glycemic management expertise.

An FDA-cleared alternative like Glucommander® shifts these burdens to a validated partner with a zero-recall safety record across 400+ hospitals.

Standardization requires three elements: validated, consistent dosing logic across every unit and shift; current visibility into glycemic performance across the system; and governance structures to sustain improvement over time.

GlytecOne supports all three. Glucommander® provides FDA-cleared, algorithm-based dosing recommendations that are consistent regardless of unit, shift, or provider. Clinicians review and confirm all recommendations. Command Center provides organized displays of current and historical glycemic data to support quality improvement and care coordination. And Glytec’s clinical team supports the governance frameworks needed to sustain change.

Insulin is consistently ranked among the highest-risk medications in hospital settings. Effective governance requires standardized dosing protocols, validated tools, clear accountability, and measurable outcomes.

Glytec recommends establishing a glycemic safety committee with cross-functional representation (quality, safety, endocrinology, nursing, pharmacy), defining clear ownership and accountability for glycemic performance, implementing validated dosing support through FDA-cleared tools, using enterprise analytics to baseline, benchmark, and track improvement, and aligning governance with CMS glycemic eCQM reporting requirements.

Sustainable improvement requires both a clinical champion who leads the cross-functional team and executive leadership who supports the investment. Change can start from the bedside or the boardroom. It lasts only when clinical leadership and financial leadership move forward together.

Yes. GlytecOne’s full platform architecture is designed and maintained in compliance with HIPAA requirements. HITRUST CSF certification validates that GlytecOne meets the rigorous information security and risk management requirements expected by enterprise health system security teams.

GlytecOne is cloud-based, reducing on-premise hardware burden and enabling automatic security updates. Security architecture details are available for review by your IT and security teams.

Published clinical evidence across 400+ hospitals demonstrates measurable results with GlytecOne and Glucommander®. Key outcomes include:

• Up to 99.8% reduction in IV patients with severe hypoglycemia events
• 62% fewer severe hypoglycemia adverse drug events vs. EndoTool, AdventHealth head-to-head)
• Up to 3.2 days reduction in average length of stay
• 35-68% reduction in 30-day readmissions for AMI, CHF, and CABG patients
• 47% reduction in nursing time vs. EndoTool
• Up to 30 minutes saved per prescriber per shift
• 90-100% clinician satisfaction
• 6-8x ROI

Individual results may vary. All outcomes are supported by peer-reviewed published evidence.

Published outcomes data demonstrates 6-8x return on investment with GlytecOne implementation. Cost avoidance is driven by multiple factors: reduced length of stay (up to 3.2 days reduction), fewer severe hypoglycemia events (conservative cost estimate of more than $10,000 per event), reduced 30-day readmissions (35-68% reduction for AMI, CHF, CABG patients), reduced point-of-care blood glucose testing (up to 30% reduction per patient), and nursing time savings (47% reduction vs. EndoTool, up to 72 minutes per nurse per patient receiving IV insulin).

Individual results may vary based on facility size, patient population, and implementation scope.

Glucommander®’s FDA-cleared, algorithm-based insulin dosing recommendations calculate doses from patient parameters and cumulative glucose response using predefined algorithm parameters. This approach helps reduce the variability and manual calculation errors that contribute to severe hypoglycemia events. Clinicians review and confirm all recommendations.

Published evidence demonstrates up to 99.8% reduction in IV patients with severe hypoglycemia events compared to paper protocols, 93% reduction in severe hypoglycemia (below 40 mg/dL) using Glucommander® IV compared to paper protocols, and 62% fewer severe hypoglycemia ADEs compared to EndoTool.

Multiple published studies demonstrate reduced length of stay with Glucommander® implementation. Results include up to 3.2 days reduction in average length of stay with implementation of Glucommander® IV and SubQ, 17.6% shorter length of stay compared to DIY/Epic approaches (5.4 days vs. 6.5 days), 31% shorter average LOS in patients with mild DKA using Glucommander® IV compared to paper protocols (3.5 vs. 5.1 days, and 24% reduction in average length of stay in whole-house implementation.

Individual results may vary based on patient population and implementation scope.

GlytecOne’s Care Enablement pillar is designed to reduce the manual workload nurses carry in glycemic management. Glucommander®’s algorithm-based dosing guidance helps reduce manual math at the point of care. Standardized workflows mean nurses manage glucose the same way every shift, reducing the variation that creates confusion and risk. Documentation support helps reduce charting time. Published evidence shows 47% reduction in nursing time compared to EndoTool and up to 72 minutes saved per nurse per patient receiving IV insulin.

Clinicians review and confirm all Glucommander® dosing recommendations. The system supports nursing decisions; it does not replace nursing judgment.

Hospitalists managing broad patient panels can benefit from GlytecOne in two ways. Glucommander® provides patient-specific, algorithm-based insulin dosing recommendations that give providers an evidence-based starting point for each patient at each glucose value. Clinicians review and confirm all recommendations. Separately, Command Center provides organized displays of current and historical patient glucose data to support awareness and prioritization, helping hospitalists identify which patients’ data patterns may warrant clinical review.

Unlike generic EHR alerts, GlytecOne’s Decision Support is purpose-built for glycemic management, with every workflow specific to glucose.

GlytecOne gives pharmacy leaders a validated dosing foundation through FDA-cleared Glucommander®. Every insulin dosing recommendation is based on validated, algorithm-based clinical logic, not locally developed hospital calculators. Clinicians review and confirm all recommendations.

Care Enablement supports high-risk insulin combination flagging and structures the pharmacist review workflow, helping to reduce verification time during high-volume periods. Standardized insulin workflows across pharmacy, nursing, and providers ensure alignment around the same validated clinical foundation. Every dosing decision and pharmacist review is logged in GlytecOne’s audit trail for medication safety reviews, Joint Commission preparation, and regulatory defensibility.

GlytecOne supports clinical leaders in three key areas. Standardization: FDA-cleared, algorithm-based dosing guidance supports protocol compliance above 90%, compared to below 60% with manual workflows. Clinicians review and confirm all recommendations. Visibility: Performance Insights through Command Center delivers longitudinal dashboards across every glycemic KPI so leaders can baseline, benchmark, and demonstrate improvement at the unit, facility, and enterprise level. CMS Readiness: eCQM-aligned reporting modules generate regulatory-ready data exports and support organizational readiness for mandatory glycemic safety reporting.

GlytecOne reduces the technical risk and maintenance burden associated with hospital-built insulin calculators. Glucommander® is FDA-cleared and validated by Glytec, meaning the clinical and technical validation responsibility does not rest with your IT team. GlytecOne integrates with Epic, Oracle Health (Cerner), and Meditech through bi-directional HL7 interfaces and single sign-on. Standard integration architecture means minimal custom development. The platform is cloud-based, HIPAA compliant, and HITRUST certified, with no on-premise infrastructure required.

A standard single-facility implementation typically takes 8 to 16 weeks. Glytec’s Solutions Engineering team leads the integration process with dedicated IT support.

GlytecOne helps executive leaders address glycemic care as an organizational risk, not just a clinical concern. Key areas include: measurable outcomes (published 6-8x ROI, reduced length of stay, fewer readmissions), CMS exposure reduction (eCQM-aligned reporting supports readiness for mandatory glycemic safety reporting), enterprise visibility (Command Center provides current and historical performance data across units and facilities to support governance), and workforce sustainability (standardized workflows help reduce clinician burden and variation).

The first step is a conversation, not a demo. Glytec works with your team to understand your current glycemic management approach, your clinical and operational priorities, and where the greatest opportunities for improvement exist. From there, Glytec can provide a customized assessment of glycemic risk and a structured implementation path aligned to your goals.

Book a discussion with Glytec’s team to begin.

Yes. Glytec offers a Glycemic Risk Assessment designed to surface hidden risk and help prioritize preventable events within your organization. This assessment can help quantify the scope of glycemic variability, identify where manual workflows may be creating avoidable risk, and build the evidence base needed to align cross-functional stakeholders around improvement.

Glytec follows a structured three-phase approach. Phase 1: Assess glycemic risk and align the cross-functional team around shared priorities. Phase 2: Configure and implement GlytecOne within your EHR environment, with Glytec’s Solutions Engineering team leading the integration. A standard single-facility implementation typically takes 8 to 16 weeks. Phase 3: Sustain improvement through governance, ongoing analytics, and clinical support. Glytec provides 24/7 clinical support after go-live.

Successful glycemic improvement efforts begin with a strong internal champion. This is typically someone who leads or can rally a cross-functional team (quality, safety, endocrinology, nursing, pharmacy), has credibility with executives, clinicians, and nursing, understands that glycemic improvement is organizational change (not just software), and can drive alignment around safety-first care.

Sustainable improvement also requires executive leadership who will fund the initiative. Change can start from the bedside or the boardroom. It lasts only when clinical leadership and financial leadership move forward together.

Glytec provides 24/7 clinical support after implementation, not a generalist help desk. Support includes ongoing clinical guidance, workflow optimization, governance support, and access to Glytec’s clinical team for glycemic management best practices. Performance Insights through Command Center provides ongoing analytics and benchmarking to sustain improvement over time.